1125 – Tracking Equitable Rollout of Doxy-PEP and CAB-LA for STI & HIV Prevention in San Francisco Clinics
Background Groundbreaking innovations in prevention of syphilis, chlamydia, and gonorrhea (STIs) with doxycycline postexposure prophylaxis (doxy-PEP) and HIV with long-acting cabotegravir (CAB-LA) have the potential to reduce population-level incidence of STIs and HIV. For maximal effectiveness, these tools must reach those with high STI and HIV rates. In San Francisco (SF) in 2024, STI rates…